highperformr logo

Biognosys's Overview

Total employees92
HeadquartersSchlieren
Founded2008

Biognosys is a leader in next-generation proteomics, dedicated to transforming life sciences by developing and applying innovative mass spectrometry-based proteomics solutions. The company provides a comprehensive suite of services and products for high-content protein discovery, quantification, and biomarker identification. Biognosys supports researchers and pharmaceutical companies worldwide in their efforts to understand complex biological systems, discover new drug targets, and develop novel diagnostics and therapies. Their proprietary technologies and data analysis software, like Spectronaut®, enable deep and precise proteome coverage, empowering breakthroughs in various research areas including drug discovery, clinical research, and diagnostics development.

Where is Biognosys's Headquarters?

HQ Function

Serves as the central hub for research and development, global operations management, corporate strategy, software development, and customer support for European and international markets.

Notable Features:

Located within the Bio-Technopark Schlieren-Zürich, providing access to a vibrant ecosystem of research institutions and biotech companies. The facility houses state-of-the-art mass spectrometry laboratories and data science infrastructure.

Work Culture:

Emphasizes innovation, scientific excellence, collaboration, quality, and a customer-centric approach. Employees are typically highly skilled scientists, bioinformaticians, and professionals passionate about advancing proteomics and its applications.

HQ Significance:

Its location in a major European biotech cluster facilitates collaborations, talent acquisition, and access to cutting-edge research. It is the birthplace of Biognosys' core technologies and continues to drive innovation in the proteomics field.

Values Reflected in HQ: Precision, innovation, scientific rigor, and collaboration are reflected in the advanced laboratory setups, data-driven approaches, and the collaborative environment of the biotech park.

Location:

Biognosys supports a global clientele through its headquarters in Switzerland and its US office in Massachusetts. The company provides its advanced proteomics services, software solutions (like Spectronaut® and TrueTarget™), and research collaboration opportunities to pharmaceutical companies, biotechnology firms, and academic research institutions across Europe, North America, Asia, and other regions worldwide. Their global reach is facilitated by direct engagement, a dedicated global commercial team, and a network of partners and distributors, ensuring access to their cutting-edge technologies for researchers globally.

Street Address:

Wagistrasse 21

City:

Schlieren

State/Province:

Zurich

Country:

Switzerland

Biognosys's Global Presence

Beverly, Massachusetts, USA

Address: 500 Cummings Center, Suite 4550, Beverly, MA 01915

To expand Biognosys' presence in the large North American life sciences market, offer localized customer support and scientific collaboration, and foster relationships with US-based research institutions and companies.

Buying Intent Signals for Biognosys

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Biognosys

As of April 2025, Biognosys' leadership includes:

Oliver Rinner, PhD - Chief Executive Officer (CEO)
Lukas Reiter, PhD - Chief Technology Officer (CTO)
Karel Novy, PhD - Chief Operating Officer (COO)
Claudio D´Angelo, PhD - Chief Business Officer (CBO)

Investors of Biognosys

Biognosys has been backed by several prominent investors over the years, including:

Dievini Hopp BioTech holding GmbH & Co. KG
HBM Healthcare Investments
Founding Investors & Private Shareholders
Schmela GmbH

Executive New Hires/Exits in the Last 12 Months

Hire0
Exits0

Based on publicly available information, there have been no major C-suite executive hires or departures widely announced by Biognosys in the last 12 months (ending May 2024), suggesting stability in top leadership. Any internal promotions or non-C-suite senior appointments may not have been broadly publicized.

Technology (Tech Stack) used by Biognosys

Discover the tools Biognosys uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Biognosys Email Formats and Examples

Biognosys likely uses standard corporate email formats. While specific internal patterns can vary, a common format for companies of this nature is [first].[last]@[companydomain.com] or [first_initial][last]@[companydomain.com]. For example, a contact like Jane Doe might have an email address such as jane.doe@biognosys.com.

[first].[last]@biognosys.com

Format

jane.doe@biognosys.com

Example

75%

Success rate

News and media

Business WireApril 16, 2024

Biognosys Announces TrueDiscovery™ Deep Leukocyte Profiling for Unbiased Discovery of Novel Targets and Biomarkers on Immune Cells

Biognosys launched its TrueDiscovery™ Deep Leukocyte Profiling platform, offering unbiased, deep profiling of over 5,000 proteins, including >1,000 surface proteins, across all major leukocyte cell types. This platform aims to accelerate drug discovery by identifying novel targets and biomarkers on immune cells....more

Business WireJanuary 9, 2024

Biognosys and Thermo Fisher Scientific Announce Co-Marketing Agreement to Advance Plasma Proteomics for Clinical Research

Biognosys and Thermo Fisher Scientific entered a co-marketing agreement to provide advanced plasma proteomics solutions for clinical research. The collaboration aims to combine Biognosys' expertise in proteomics services and software with Thermo Fisher's Orbitrap mass spectrometry platforms....more

Business WireNovember 7, 2023

Biognosys Expands TrueTarget™ Platform With Lysosome Targeting Capabilities to Accelerate Targeted Protein Degradation Drug Discovery

Biognosys announced the expansion of its TrueTarget™ proteomics platform with new lysosome-focused capabilities, designed to support the discovery and development of targeted protein degrader (TPD) drugs by identifying proteins directed to the lysosome for degradation....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Biognosys, are just a search away.